Oncopeptides names new CEO
16 November 2021 -

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a Sweden-based biotech company focused on research and development of therapies for difficult-to-treat haematological diseases, announced on Monday that it has named Jakob Lindberg as its new chief executive officer.

Lindberg is to replace Marty J Duvall, who has been the CEO since July 1, 2020.

Lindberg has served as the CEO of Oncopeptides from the restart of Oncopeptides AB (publ) in 2011, until June 2020. Presently, he holds the position of chief scientific officer for the company.